Huyen Cao

InstitutionGilead Sciences
AddressFoster City
California
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 8 Covid-19 publications, with a maximum of 2 publications in March 2021
    All Publications
    Bar chart showing 62 publications over 19 distinct years, with a maximum of 6 publications in 2005 and 2007
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Goldman DL, Aldrich ML, Hagmann SHF, Bamford A, Camacho-Gonzalez A, Lapadula G, Lee P, Bonfanti P, Carter CC, Zhao Y, Telep L, Pikora C, Naik S, Marshall N, Katsarolis I, Das M, DeZure A, Desai P, Cao H, Chokkalingam AP, Osinusi A, Brainard DM, Méndez-Echevarría A. Compassionate Use of Remdesivir in Children With Severe COVID-19. Pediatrics. 2021 05; 147(5). PMID: 33883243.
      Citations: 3     Fields:    Translation:Humans
    2. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 05; 60(5):569-583. PMID: 33782830.
      Citations: 12     Fields:    Translation:HumansAnimals
    3. Juneja K, Humeniuk R, Porter D, Cao H, Feng J. Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?" Antimicrob Agents Chemother. 2021 03 18; 65(4). PMID: 33558289.
      Citations:    Fields:    Translation:Humans
    4. Citations: 79     Fields:    Translation:Humans
    5. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 09 15; 324(11):1048-1057. PMID: 32821939.
      Citations: 279     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    6. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci. 2020 09; 13(5):896-906. PMID: 32589775.
      Citations: 53     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    7. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837. PMID: 32459919.
      Citations: 368     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    8. Citations: 1017     Fields:    Translation:HumansCellsPHPublic Health